SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Interestingly, in a rat model of NAFLD/NASH, the administration of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, alleviated NASH also through a reduced de novo lipogenesis mediated by an upregulation of FXR/SHP and a downregulation of LXRα/SREBP-1c in the liver [277].